Table 2.
Prevalence of dermatosis groups treated as new cases at the FMB-Unesp de Botucatu (SP) Dermatology Service in 2003 and 2014
| Diagnostic group | 2003 | 2014 | RR | CI 95% | P* | |||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | |||||
| Inflammatory dermatoses | ||||||||
| Alopecia areata | 22 | 1.9% | 18 | 1.7% | 0.9 | 0.6 a | 1.3 | 0.41 |
| Acne | 106 | 9.1% | 133 | 12.3% | 1.4 | 1.2 a | 1.5 | <0.01 |
| Bullous dermatoses disease | 4 | 0.3% | 3 | 0.3% | 0.8 | 0.3 a | 1.9 | 0.40 |
| Atopic dermatitis | 13 | 1.1% | 17 | 1.6% | 1.4 | 1.0 to | 1.9 | 0.17 |
| Scleroderma | 13 | 1.1% | 6 | 0.6% | 0.5 | 0.3 to | 1.0 | 0.20 |
| Drug reactions | 14 | 1.2% | 3 | 0.3% | 0.2 | 0.1 to | 0.7 | 0.03 |
| Lichenoid eruptions | 16 | 1.4% | 27 | 2.5% | 1.8 | 1.4 to | 2.3 | 0.02 |
| Lupus erythematosus | 17 | 1.5% | 14 | 1.3% | 0.9 | 0.6 to | 1.3 | 0.41 |
| Other eczemas | 170 | 14.5% | 103 | 9.6% | 0.7 | 0.6 to | 0.8 | 0.02 |
| Psoriasis | 45 | 3.8% | 49 | 4.5% | 1.2 | 1.0 to | 1.4 | 0.15 |
| Rosacea | 7 | 0.6% | 12 | 1.1% | 1.9 | 1.3 to | 2.6 | 0.11 |
| Urticaria/Angioedema | 50 | 4.3% | 20 | 1.9% | 0.4 | 0.3 to | 0.6 | 0.01 |
| Vitiligo | 43 | 3.7% | 29 | 2.7% | 0.7 | 0.6 to | 1.0 | 0.29 |
| Infectious dermatoses | ||||||||
| Leprosy | 14 | 1.2% | 19 | 1.8% | 1.5 | 1.1 to | 2.0 | 0.14 |
| Hidradenitis suppurativa | 3 | 0.3% | 10 | 0.9% | 3.6 | 2.7 to | 4.9 | 0.03 |
| Bacterial infection | 16 | 1.4% | 6 | 0.6% | 0.4 | 0.2 to | 0.8 | 0.10 |
| Infestations | 6 | 0.5% | 4 | 0.4% | 0.7 | 0.3 to | 1.5 | 0.38 |
| Deep mycoses | 6 | 0.5% | 5 | 0.5% | 0.9 | 0.5 to | 1.7 | 0.40 |
| Superficial mycoses | 148 | 12.6% | 47 | 4.4% | 0.3 | 0.3 to | 0.4 | <0.01 |
| Syphilis | 5 | 0.4% | 12 | 1.1% | 2.6 | 1.9 to | 3.6 | 0.04 |
| Anogenital wart | 11 | 0.9% | 45 | 4.2% | 4.4 | 3.9 to | 5.1 | <0.01 |
| Viral wart | 37 | 3.2% | 13 | 1.2% | 0.4 | 0.2 to | 0.6 | 0.01 |
| Neoplastic dermatoses | ||||||||
| Cyst/Lipoma | 66 | 5.6% | 15 | 1.4% | 0.2 | 0.2 to | 0.4 | <0.01 |
| Lymphoma | 6 | 0.5% | 9 | 0.8% | 1.6 | 1.1 to | 2.5 | 0.20 |
| Melanoma | 12 | 1.0% | 9 | 0.8% | 0.8 | 0.5 to | 1.3 | 0.39 |
| NMSC | 222 | 19.0% | 220 | 20.4% | 1.1 | 1.0 to | 1.2 | 0.03 |
| Melanocytic nevi | 52 | 4.4% | 22 | 2.0% | 0.5 | 0.3 to | 0.7 | 0.01 |
| Seborrheic keratosis | 65 | 5.6% | 25 | 2.3% | 0.4 | 0.3 to | 0.6 | <0.01 |
| Other dermatoses | ||||||||
| Androgenetic alopecia | 16 | 1.4% | 21 | 1.9% | 1.4 | 1.1 to | 1.9 | 0.14 |
| Telogen effluvium | 13 | 1.1% | 17 | 1.6% | 1.4 | 1.0 to | 1.9 | 0.17 |
| Genodermatoses | 12 | 1.0% | 14 | 1.3% | 1.3 | 0.9 to | 1.8 | 0.26 |
| Melasma | 29 | 2.5% | 68 | 6.3% | 2.5 | 2.2 to | 2.9 | <0.01 |
| Onychocryptosis | 6 | 0.5% | 3 | 0.3% | 0.5 | 0.2 to | 1.4 | 0.31 |
| Other | 151 | 12.9% | 124 | 11.5% | 0.9 | 0.8 to | 1.0 | 0.40 |
| Pruritus | 8 | 0.7% | 22 | 2.0% | 3.0 | 2.4 to | 3.7 | <0.01 |
| Psicodermatoses | 22 | 1.9% | 26 | 2.4% | 1.3 | 1.0 to | 1.7 | 0.17 |
| Chronic ulcer | 36 | 3.1% | 22 | 2.0% | 0.7 | 0.5 to | 0.9 | 0.22 |
*
P-value of the residual analysis (adjusted and standardized results); RR: Relative risk; 95% CI: 95% confidence interval; NMSC: Non-melanoma skin cancer, including actinic keratosis